Brokerages Set Audentes Therapeutics Inc (BOLD) Target Price at $35.00

Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have earned an average recommendation of “Hold” from the fifteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $35.11.

A number of equities research analysts have recently commented on the company. BidaskClub upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. HC Wainwright set a $40.00 target price on Audentes Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 25th. Cowen assumed coverage on Audentes Therapeutics in a research report on Friday, September 7th. They set a “sell” rating and a $20.00 target price on the stock. B. Riley assumed coverage on Audentes Therapeutics in a research report on Friday, September 7th. They set a “sell” rating and a $20.00 target price on the stock. Finally, Guggenheim assumed coverage on Audentes Therapeutics in a research report on Tuesday, October 9th. They set a “neutral” rating on the stock.

In related news, CEO Matthew R. Patterson sold 12,952 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $40.00, for a total value of $518,080.00. Following the transaction, the chief executive officer now directly owns 12,952 shares of the company’s stock, valued at approximately $518,080. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $36.88, for a total transaction of $368,800.00. Following the completion of the transaction, the vice president now directly owns 100 shares in the company, valued at $3,688. The disclosure for this sale can be found here. Insiders sold a total of 77,039 shares of company stock worth $2,925,260 over the last ninety days. 6.60% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. Artal Group S.A. lifted its stake in Audentes Therapeutics by 5.9% in the 3rd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $9,898,000 after purchasing an additional 14,000 shares in the last quarter. BlackRock Inc. lifted its stake in Audentes Therapeutics by 4.5% in the 3rd quarter. BlackRock Inc. now owns 2,567,986 shares of the biotechnology company’s stock worth $101,667,000 after purchasing an additional 109,815 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Audentes Therapeutics by 40.3% in the 3rd quarter. Alliancebernstein L.P. now owns 660,281 shares of the biotechnology company’s stock worth $26,141,000 after purchasing an additional 189,825 shares in the last quarter. Jennison Associates LLC lifted its stake in Audentes Therapeutics by 0.8% in the 3rd quarter. Jennison Associates LLC now owns 1,028,668 shares of the biotechnology company’s stock worth $40,725,000 after purchasing an additional 8,112 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its stake in Audentes Therapeutics by 243.6% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 238,800 shares of the biotechnology company’s stock worth $9,454,000 after purchasing an additional 169,300 shares in the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:BOLD opened at $24.00 on Wednesday. Audentes Therapeutics has a 52 week low of $19.62 and a 52 week high of $46.18. The stock has a market cap of $904.48 million, a PE ratio of -7.06 and a beta of 1.99.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.09). During the same quarter in the previous year, the business posted ($0.88) earnings per share. Analysts predict that Audentes Therapeutics will post -3.39 earnings per share for the current fiscal year.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Recommended Story: What are the most popular ETFs

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply